Diverse effects of interferon alpha on the establishment and reversal of HIV latency
Open Access
- 28 February 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Pathogens
- Vol. 16 (2), e1008151
- https://doi.org/10.1371/journal.ppat.1008151
Abstract
HIV latency is the major barrier to a cure for people living with HIV (PLWH) on antiretroviral therapy (ART) because the virus persists in long-lived non-proliferating and proliferating latently infected CD4+ T cells. Latently infected CD4+ T cells do not express viral proteins and are therefore not visible to immune mediated clearance. Therefore, identifying interventions that can reverse latency and also enhance immune mediated clearance is of high interest. Interferons (IFNs) have multiple immune enhancing effects and can inhibit HIV replication in activated CD4+ T cells. However, the effects of IFNs on the establishment and reversal of HIV latency is not understood. Using an in vitro model of latency, we demonstrated that plasmacytoid dendritic cells (pDC) inhibit the establishment of HIV latency through secretion of type I IFNα, IFNβ and IFNω but not IFNε or type III IFNλ1 and IFNλ3. However, once latency was established, IFNα but no other IFNs were able to efficiently reverse latency in both an in vitro model of latency and CD4+ T cells collected from PLWH on suppressive ART. Binding of IFNα to its receptor expressed on primary CD4+ T cells did not induce activation of the canonical or non-canonical NFκB pathway but did induce phosphorylation of STAT1, 3 and 5 proteins. STAT5 has been previously demonstrated to bind to the HIV long terminal repeat and activate HIV transcription. We demonstrate diverse effects of interferons on HIV latency with type I IFNα; inhibiting the establishment of latency but also reversing HIV latency once latency is established. Antiretroviral therapy (ART) cannot cure HIV or eliminate infection from long-lived and proliferating latently infected CD4+ T cells. Plasmacytoid dendritic cells (pDC) are major producers of interferons (IFNs), which have multiple effects on viral replication and immunity including suppression of viral expression that could favor HIV latency. Van Der Sluis et al. show that type I IFNs inhibit the establishment of HIV latency, however, once established, latency can be reversed by IFNα but not by other type I or type III IFNs. These observations demonstrate that pDC through type I IFNs are important in HIV latency and can potentially be manipulated to eliminate latent infection.Keywords
This publication has 81 references indexed in Scilit:
- Interferon-stimulated genes and their antiviral effector functionsCurrent Opinion in Virology, 2011
- Thymic plasmacytoid dendritic cells are susceptible to productive HIV-1 infection and efficiently transfer R5 HIV-1 to thymocytes in vitroRetrovirology, 2011
- A diverse range of gene products are effectors of the type I interferon antiviral responseNature, 2011
- Phospho Flow Cytometry Methods for the Analysis of Kinase Signaling in Cell Lines and Primary Human Blood SamplesMethods in Molecular Biology, 2010
- Establishment of HIV-1 latency in resting CD4 + T cells depends on chemokine-induced changes in the actin cytoskeletonProceedings of the National Academy of Sciences of the United States of America, 2010
- Partial Inhibition of Human Immunodeficiency Virus Replication by Type I Interferons: Impact of Cell-to-Cell Viral TransferJournal of Virology, 2009
- TRIM family proteins and their emerging roles in innate immunityNature Reviews Immunology, 2008
- Interferon-inducible antiviral effectorsNature Reviews Immunology, 2008
- Mini ReviewHuman Interferons Alpha, Beta and OmegaGrowth Factors, 2004
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997